Here are three reasons why there are better opportunities than TXG and a stock we'd rather own. Founded in 2012, 10x Genomics (NASDAQ:TXG) develops single-cell and spatial genomics solutions ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

The Lenovo Legion Go S highlights Lenovo's commitment to this growing category of devices, and it's absolutely a more refined, elegant gaming handheld than the Legion Go that came before it.

The Lenovo Legion Go S is an incredibly ergonomic handheld gaming PC that feels great in your hands. But Windows makes the whole experience feel awkward. The Steam Deck OLED offers better battery ...

Serge Saxonov, the Chief Executive Officer of $TXG, sold 7,942 shares of the company on 02-28-2025 for an estimated $84,393. We received data on the trade from a ...

You'll get the most out of your Lenovo Legion Go S handheld with these accessories and add-ons. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.

ALAN MATEO, a director at $TXG, bought 40,000 shares of the company on 02-21-2025 for an estimated $445,572. This trade was reported by Quiver Quantitative using data ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from Outperform to Market Perform. Analyst Price Forecast Suggests 71.13% Upside ...

10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

10x Genomics Price Performance Shares of TXG opened at $12.31 on Tuesday. The firm has a market cap of $1.49 billion, a PE ratio of -8.05 and a beta of 1.85. The stock’s fifty day moving average ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the life science tools and diagnostics group post the ...